Provided by Tiger Trade Technology Pte. Ltd.

Mistras Group Inc

18.96
-0.5500-2.82%
Post-market: 18.960.00000.00%19:30 EDT
Volume:360.51K
Turnover:6.86M
Market Cap:603.24M
PE:23.05
High:19.60
Open:19.47
Low:18.66
Close:19.51
52wk High:20.20
52wk Low:9.24
Shares:31.82M
Float Shares:13.63M
Volume Ratio:1.24
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8225
EPS(LYR):0.5300
ROE:11.78%
ROA:6.35%
PB:2.51
PE(LYR):35.77

Loading ...

Roth MKM Sticks to Its Buy Rating for Mistras Group (MG)

TIPRANKS
·
May 08

MG Home Co Raises FY Net View to Y1.16B

Dow Jones
·
May 07

Mistras Group Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

MISTRAS Group Q1 Adj. EPS $0.08 Beats $0.05 Estimate, Sales $169.034M Beat $166.227M Estimate

Benzinga Earnings
·
May 06

MISTRAS FY26 Q1 returns to profit of $2.4 million; revenue rises 4.6% to $169 million

Reuters
·
May 06

MISTRAS Q1 revenue rises 4.6%, beats estimates, Adjusted EBITDA misses

Reuters
·
May 06

BRIEF-MISTRAS Q1 Revenue USD 169 Million

Reuters
·
May 06

Mistras Group Inc: Oil and Gas Field Inspections May Continue to Be Impacted by High Crude Oil Prices Into Q2 of 2026

THOMSON REUTERS
·
May 06

Mistras Q1 Gross Profit USD 44.7 Million

THOMSON REUTERS
·
May 06

Mistras Group Inc - Reaffirms FY2026 Guidance

THOMSON REUTERS
·
May 06

Mistras Q1 Gross Margin 26.5%

THOMSON REUTERS
·
May 06

MISTRAS Announces First Quarter 2026 Results

GlobeNewswire
·
May 06

Mistras Group Inc expected to post earnings of 5 cents a share - Earnings Preview

Reuters
·
May 02

Roth Capital Partners Initiates Mistras at Buy With $22 Price Target

MT Newswires Live
·
Apr 30

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Apr 30

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

GlobeNewswire
·
Apr 23

China Medical System’s MG‑K10 Allergy Drug NDA Accepted in China

TIPRANKS
·
Apr 23

CMS Announces NMPA Acceptance of New Drug Application for MG-K10 in Seasonal Allergic Rhinitis

Stock News
·
Apr 23

MISTRAS Group schedules quarterly results conference call

Reuters
·
Apr 22

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

GlobeNewswire
·
Apr 21